新しい抗緑膿菌性抗生剤Amikacin （BB-K8）の眼内移行ならびに臨床的検討

Intraocular Penetrations and Clinical Evaluation of Amikacin (BB K8) in Ocular Infections

緒言

　近年，新しい抗緑膿菌性抗生剤が相ついで登場しているが，なかでもアミノ配糖体抗生剤の耐性機序が解明されたことにもとづいて，いくつかの半合成アミノ配糖体抗生物質が検討されている。

　Amikacin （BB-K8）もその一つで，Kana—mycin Aの構成成分である2—Deoxystrepta—mine部分のC−1アミノ基をL （—）—γ—Amino—α—hydroxybutyric acid （L-HABA）でアシル化してえられた抗生剤で，第1図の構造式で示される。

The intraocular penetrations in rabbit eye and clinical evaluation in ocular infections of Ami-kacin (BB-K8) were performed.

The results were summerized as follows.

1) Ocular penetration

A 0.5% solution was applied to the rabbit's eye 5 times at five minutes intervals. The aqueous level was recognized 30 minutes after instillation. Peak level, 5.46 μg/ml, was reached after one hour, followed by rather rapid decline. Amikacin was not detectable 6 hours after application.